Hims & Hers Health, Inc. (HIMS) ended the recent trading session at $27.23, demonstrating a +1.04% swing from the preceding day's closing price. This change outpaced the S&P 500's 0.13% gain on the ...

Eli Lilly and Co. shares surged after data showed its experimental weight-loss pill worked as well as the Ozempic shot.

The company's breakthrough puts the market one step closer to having an injection-free alternative for the treatment of ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV ...

BofA Securities reiterated its Underperform rating on Hims & Hers Health (NYSE:HIMS), keeping its price target steady at $22, ...

The stock market fell sharply anew on Wednesday, with all major indices ending in the red, as investor sentiment was dampened ...

HIMS has experienced similar dramatic drops before. During the 2022 inflation surge, the stock fell 87%, and in 2020, it ...

Trial data data showed Lilly's experimental weight-loss pill worked as well as the Ozempic shot, bringing it one step closer ...

Weight loss platform Noom launched a full-page print ad in The Wall Street Journal this week, calling on policymakers to ...

A diverse range of medical specialists offer unique expertise for obesity treatment. “Endocrinologists, bariatricians, obesity specialists and psychiatrists can prescribe weight loss medication,” ...

Jefferies analyst Glen Santangelo raised the firm’s price target on Hims & Hers to $25 from $21 and keeps a Hold rating on the shares. A ...